Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2015

Liu L, Cohen C, Siddiqui MT. Expression of ProEx C in primary and metastatic urothelial carcinoma. Diagn Cytopathol. 2015;43(3):181-7.

Dyhdalo KS, Booth CN, Brainard JA, Croyle MC, Kolosiwsky AM, Goyal A, et al. Utility of GATA3, mammaglobin, GCDFP-15, and ER in the detection of intrathoracic metastatic breast carcinoma. J Am Soc Cytopathol. 2015;4(4):218-224.

O-Sullivan IS, Zhang W, Wasserman DH, Liew CW, Liu J, Paik J, et al. Erratum: FoxO1 integrates direct and indirect effects of insulin on hepatic glucose production and glucose utilization. Nat Commun. 2015;6:7861.

Jiang P, Scarpa JR, Fitzpatrick K, Losic B, Gao VD, Hao K, et al. A systems approach identifies networks and genes linking sleep and stress: implications for neuropsychiatric disorders. Cell Rep. 2015;11(5):835-48.

Magro CM, Toledo-Garcia A, Pala O, Momtahen S, Shapiro L. Opioid associated intravenous and cutaneous microvascular drug abuse (skin-popping) masquerading as Degos disease (malignant atrophic papulosis) with multiorgan involvement. Dermatol Online J. 2015;21(9).

Liu Y, Magro C, Loewenstein JI, Makar RS, Stowell CP, Dzik WH, et al. A Man with Paraneoplastic Retinopathy plus Small Fiber Polyneuropathy Associated with Waldenström Macroglobulinemia (Lymphoplasmacytic Lymphoma): Insights into Mechanisms. Ocul Immunol Inflamm. 2015;23(5):405-9.

Arvanitakis Z, Brey RL, Rand JH, Schneider JA, Capuano AW, Yu L, et al. Relation of antiphospholipid antibodies to postmortem brain infarcts in older people. Circulation. 2015;131(2):182-9.

Tyekucheva S, Martin NE, Stack EC, Wei W, Vathipadiekal V, Waldron L, et al. Comparing Platforms for Messenger RNA Expression Profiling of Archival Formalin-Fixed, Paraffin-Embedded Tissues. J Mol Diagn. 2015;17(4):374-81.

Crescenzo R, Abate F, Lasorsa E, Tabbo' F, Gaudiano M, Chiesa N, et al. Convergent mutations and kinase fusions lead to oncogenic STAT3 activation in anaplastic large cell lymphoma. Cancer Cell. 2015;27(4):516-32.

Niesvizky R, Badros AZ, Costa LJ, Ely SA, Singhal SB, Stadtmauer EA, et al. Phase 1/2 study of cyclin-dependent kinase (CDK)4/6 inhibitor palbociclib (PD-0332991) with bortezomib and dexamethasone in relapsed/refractory multiple myeloma. Leuk Lymphoma. 2015;56(12):3320-8.